Breaking the dichotomy of HER2: highlighting the flaws of simplifying variables.
作者信息
Pozin Jacob, Shaw Reid, Weiss Jennifer
机构信息
Department of Hematology/Oncology, Loyola University Medical Center, Maywood, IL, United States.
出版信息
Front Oncol. 2025 May 9;15:1494417. doi: 10.3389/fonc.2025.1494417. eCollection 2025.
Abstract
摘要
相似文献
1
Breaking the dichotomy of HER2: highlighting the flaws of simplifying variables.打破HER2的二分法：凸显简化变量的缺陷。
Front Oncol. 2025 May 9;15:1494417. doi: 10.3389/fonc.2025.1494417. eCollection 2025.
2
Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging.通过单粒子量子点成像对HER2蛋白表达的乳腺癌进行定量诊断。
Cancer Med. 2016 Oct;5(10):2813-2824. doi: 10.1002/cam4.898. Epub 2016 Sep 26.
3
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status.HER2 表达的三分法为我们深入理解和管理基于 HER2 状态的乳腺癌提供了新的视角。
Int J Cancer. 2023 Oct 1;153(7):1324-1336. doi: 10.1002/ijc.34570. Epub 2023 Jun 14.
4
HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.在一项针对接受曲妥珠单抗治疗的转移性乳腺癌患者的基于人群的研究中进行人表皮生长因子受体2（HER2）检测。
Arch Pathol Lab Med. 2008 Jan;132(1):61-5. doi: 10.5858/2008-132-61-HTIAPS.
5
Current issues in ER and HER2 testing by IHC in breast cancer.乳腺癌免疫组化检测雌激素受体（ER）和人表皮生长因子受体2（HER2）的当前问题
Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34.
6
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.曲妥珠单抗治疗后HER2阳性胃癌或胃食管癌中HER2缺失：对进一步临床研究的意义
Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.
7
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.（64）Cu-DOTA-曲妥珠单抗PET成像与HER2阳性乳腺癌患者脑转移灶的HER2特异性
EJNMMI Res. 2015 Mar 12;5:8. doi: 10.1186/s13550-015-0082-6. eCollection 2015.
8
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.NSABP B-47/NRG 肿瘤学 III 期随机试验，比较了曲妥珠单抗辅助化疗与无曲妥珠单抗辅助化疗在经 FISH 检测 HER2 阴性、免疫组织化学（IHC）1+或 2+的高危浸润性乳腺癌中的应用。
J Clin Oncol. 2020 Feb 10;38(5):444-453. doi: 10.1200/JCO.19.01455. Epub 2019 Dec 10.
9
Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study.曲妥珠单抗-美坦新偶联物在人表皮生长因子受体 2 免疫组织化学评分为 2 且荧光原位杂交阳性的转移性乳腺癌患者中的疗效较低，与免疫组织化学评分为 3 的患者相比：一项回顾性研究。
Anticancer Drugs. 2020 Oct;31(9):973-978. doi: 10.1097/CAD.0000000000000939.
10
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.HER2 低表达乳腺癌——来自正在进行的研究的诊断挑战和见解：播客。
Target Oncol. 2023 May;18(3):313-319. doi: 10.1007/s11523-023-00964-8. Epub 2023 May 3.
本文引用的文献
1
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.符合 2023 年 ASCO/CAP 更新和 2023 年 ESMO 关于 HER2 低乳腺癌共识声明的 HER2 检测标准化病理报告。
Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28.
2
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.人表皮生长因子受体 2 检测在乳腺癌中的应用：ASCO-美国病理学家学会指南更新。
J Clin Oncol. 2023 Aug 1;41(22):3867-3872. doi: 10.1200/JCO.22.02864. Epub 2023 Jun 7.
3
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.早期乳腺癌中 ERBB2-低表达的预后和生物学意义。
JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286.
4
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
5
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.定量测量 HER2 表达以细分 ERBB2 未扩增的乳腺癌。
Lab Invest. 2022 Oct;102(10):1101-1108. doi: 10.1038/s41374-022-00804-9. Epub 2022 May 20.
6
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.检测乳腺癌组织中低 ERBB2 蛋白的表达。
JAMA Oncol. 2022 Apr 1;8(4):1-4. doi: 10.1001/jamaoncol.2021.7239.
7
Evolution of HER2-low expression from primary to recurrent breast cancer.HER2低表达在原发性乳腺癌至复发性乳腺癌中的演变。
NPJ Breast Cancer. 2021 Oct 12;7(1):137. doi: 10.1038/s41523-021-00343-4.
8
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.曲妥珠单抗治疗早期 HER2 阳性乳腺癌：来自 7 项随机试验的 13864 名女性的荟萃分析。
Lancet Oncol. 2021 Aug;22(8):1139-1150. doi: 10.1016/S1470-2045(21)00288-6.
9
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.临床 HER2 阴性患者中低水平 HER2 表达的预后影响。
Eur J Cancer. 2021 Sep;155:1-12. doi: 10.1016/j.ejca.2021.06.033. Epub 2021 Jul 23.
10
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.免疫肽富集和靶向质谱法检测福尔马林固定石蜡包埋和冷冻乳腺癌组织中人表皮生长因子受体 2 的定量分析。
Clin Chem. 2021 Jul 6;67(7):1008-1018. doi: 10.1093/clinchem/hvab047.
Zotero 插件